| Literature DB >> 30157431 |
J Patrick Murphy1, Michael A Giacomantonio2, Joao A Paulo3, Robert A Everley3, Barry E Kennedy1, Gopal P Pathak1, Derek R Clements2, Youra Kim2, Cathleen Dai4, Tanveer Sharif1, Steven P Gygi5, Shashi Gujar6.
Abstract
NAD+ is a key metabolic redox cofactor that is regenerated from nicotinamide through the NAD+ salvage pathway. Here, we find that inhibiting the NAD+ salvage pathway depletes serine biosynthesis from glucose by impeding the NAD+-dependent protein, 3-phosphoglycerate dehydrogenase (PHGDH). Importantly, we find that PHGDHhigh breast cancer cell lines are exquisitely sensitive to inhibition of the NAD+ salvage pathway. Further, we find that PHGDH protein levels and those of the rate-limiting enzyme of NAD+ salvage, NAMPT, correlate in ER-negative, basal-like breast cancers. Although NAD+ salvage pathway inhibitors are actively being pursued in cancer treatment, their efficacy has been poor, and our findings suggest that they may be effective for PHGDH-dependent cancers.Entities:
Keywords: FK866; NAD(+) salvage; PHGDH; breast cancer; complex I; metabolomics; quantitative proteomics; serine biosynthesis
Mesh:
Substances:
Year: 2018 PMID: 30157431 PMCID: PMC6402325 DOI: 10.1016/j.celrep.2018.07.086
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423